Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alpha cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    179 result(s) found for: Alpha cells. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2011-006270-13 Sponsor Protocol Number: XCEL-MEN-01 Start Date*: 2013-01-08
    Sponsor Name:Banc de Sang i Teixits
    Full Title: A phase I-IIa safety and efficacy pilot clinical trial of intraarticular administration of autologous mesenchymal stem cells in meniscus injury
    Medical condition: Degenerative meniscal lesion
    Disease: Version SOC Term Classification Code Term Level
    15.0 10028395 - Musculoskeletal and connective tissue disorders 10069364 Meniscal degeneration PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003295-12 Sponsor Protocol Number: 15022013 Start Date*: 2013-10-31
    Sponsor Name:Roskilde University Hospital
    Full Title: Combination Therapy Interferon Alpha + JAK1-2 Inhibitor in The Ph-Negative Chronic Myeloid Neoplasms
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10028538 Myelofibrosis with myelometaplasia LLT
    18.1 100000004864 10036061 Polycythemia vera LLT
    18.1 100000004864 10053134 Osteomyelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-005025-23 Sponsor Protocol Number: XCEL-PSART-01 Start Date*: 2014-03-11
    Sponsor Name:Banc de Sang i Teixits (BST)
    Full Title: A phase IIa, unicenter, prospective, randomized, parallel, two-arms, single-dose, open-label with blinded assessor pilot clinical trial to assess ex vivo expanded adult autologous mesenchymal strom...
    Medical condition: pseudarthrosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10048617 Pseudarthrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005668-28 Sponsor Protocol Number: AGAL06207 Start Date*: 2008-07-29
    Sponsor Name:Genzyme Europe BV
    Full Title: A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (agalsidase beta) in Treatment-Naive Male Pediatric Patients with Fabry Disease Without Severe Symp...
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (Completed) NL (Completed) PT (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-001838-13 Sponsor Protocol Number: FAB-CL-205 Start Date*: 2009-05-05
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: Open Label Extension Study to Evaluate the Long-term Safety Tolerability and Pharmacodynamics of AT1001 in Patients with Fabry Disease
    Medical condition: Fabry Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002154-32 Sponsor Protocol Number: AT2220-010 Start Date*: 2011-12-07
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: AN OPEN-LABEL MULTI-CENTER, INTERNATIONAL STUDY TO INVESTIGATE DRUG-DRUG INTERACTIONS BETWEEN AT2220 AND ALGLUCOSIDASE ALFA IN PATIENTS WITH POMPE DISEASE
    Medical condition: Pompe Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10036143 Pompe's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002009-25 Sponsor Protocol Number: SARSCov2EFTI1.0 Start Date*: 2020-10-01
    Sponsor Name:Fakultní nemocnice Plzeň
    Full Title: The efficacy and safety of Eftilagimod Alpha Treatment by immune modulation in COVID-19 disease (EAT COVID trial)
    Medical condition: COVID-19 disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004786-40 Sponsor Protocol Number: PB-102-F01 Start Date*: 2013-05-10
    Sponsor Name:Protalix Ltd.
    Full Title: A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks ...
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011397-14 Sponsor Protocol Number: TUD-EPPSOR-039 Start Date*: 2009-12-07
    Sponsor Name:Technical University of Dresden
    Full Title: Effect of anti-TNF-alpha therapy on endothelial progenitor cells and endothelial dysfunction in patients with psoriasis without risk factors for atherosclerosis
    Medical condition: Psoriasis vulgaris
    Disease:
    Population Age: Adults Gender:
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022709-16 Sponsor Protocol Number: AT1001-013 Start Date*: 2011-09-12
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: AN OPEN-LABEL PHASE 2A STUDY TO INVESTIGATE DRUG-DRUG INTERACTIONS BETWEEN AT1001 (MIGALASTAT HYDROCHLORIDE) AND AGALSIDASE IN SUBJECTS WITH FABRY DISEASE
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001966-14 Sponsor Protocol Number: AGAL19110 Start Date*: 2012-10-25
    Sponsor Name:Genzyme, a Sanofi Company
    Full Title: A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients with Fabry Disease
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    15.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-013459-31 Sponsor Protocol Number: AT1001-011 Start Date*: 2009-12-10
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS
    Medical condition: Fabry Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Completed) NL (Completed) BE (Completed) ES (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022636-37 Sponsor Protocol Number: AT1001-012 Start Date*: 2011-01-18
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF AT1001 AND ENZYME REPLACEMENT THERAPY (ERT) IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS, WHO WERE PREVIOU...
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DK (Completed) AT (Completed) GR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018901-12 Sponsor Protocol Number: ADPP-002ENM-DA-017 Start Date*: 2010-10-20
    Sponsor Name:Medical University Graz, Department of Internal Medicine, Div. Endocrinology and Metabolism [...]
    1. Medical University Graz, Department of Internal Medicine, Div. Endocrinology and Metabolism
    2.
    Full Title: Placebo controlled study on effects of vitamin D supplementation in type 1 diabetic subjects on immunological, endocrine and metabolic parameters: Step 2 of the Austrian Diabetes Prevention Program...
    Medical condition: To evaluate whether vitamin D supplementation in type 1 diabetic subjects significantly alters the proportion of regulatory T-cells of all circulating CD4 positive T-cells.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010335-41 Sponsor Protocol Number: RRK3728 Start Date*: 2009-06-30
    Sponsor Name:University of Birmingham
    Full Title: A MULTICENTRE, PHASE II, OPEN LABEL, RANDOMISED CONTROLLED TRIAL OF REPEATED AUTOLOGOUS INFUSIONS OF G-CSF MOBILISED CD133+ BONE MARROW STEM CELLS IN PATIENTS WITH CIRRHOSIS
    Medical condition: Liver Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10001806 Alpha-1 anti-trypsin deficiency PT
    14.1 10019805 - Hepatobiliary disorders 10009211 Cirrhosis liver LLT
    14.1 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    14.1 10019805 - Hepatobiliary disorders 10064844 Compensated cirrhosis LLT
    14.1 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-015523-91 Sponsor Protocol Number: ENM-EA-011 Start Date*: 2010-01-21
    Sponsor Name:Medizinische Universiätsklinik Graz, Abteilung für Endokrinologie und Nuklearmedizin
    Full Title: Placebo controlled study on effects of vitamin D supplementation in healthy women and men on immunological, endocrine and metabolic parameters
    Medical condition: healthy volunteers. The intended indication for the investigated product is prevention and treatment of immunological (e.g. type 1 diabetes), endocrine (e.g. endocrine hypertension), metabolic (e.g...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000363-28 Sponsor Protocol Number: GBI001 Start Date*: 2006-10-03
    Sponsor Name:Greater Glasgow Health Board [...]
    1. Greater Glasgow Health Board
    2. Glasgow University
    Full Title: DIFFERENTIATING THE MECHANISM OF ACTION OF ANTI TNF-alpha AGENTS
    Medical condition: Rheumatoid arthritis and Psoriatic arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022103-21 Sponsor Protocol Number: TUE-002 Start Date*: 2011-04-08
    Sponsor Name:University Hospital Tübingen
    Full Title: Neoadjuvant treatment of locoregional metastases in malignant melanoma (AJCC stage IIIB/C) with Multiferon: a phase IIa DeCOG trial
    Medical condition: The study is an open label, multicenter phase IIa clinical trial which is designed as a pilot project in order to establish the efficacy and tolerability of Multiferon as a neoadjuvant treatment o...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000734-19 Sponsor Protocol Number: XCEL-MS-02 Start Date*: 2014-04-10
    Sponsor Name:Banc de Sang i Teixits
    Full Title: Treatment of autologous mesenchymal stem cells derived from bone marrow as a potential therapeutic strategy for the treatment of multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-004711-35 Sponsor Protocol Number: 112147 Start Date*: 2008-10-07
    Sponsor Name:GlaxoSmithKline S.A.
    Full Title: Estudio de vacunación, fase III, observador ciego, aleatorizado (3:3:2), control activo, multinacional, multicéntrico para evaluar la respuesta inmune celular y humoral de la vacuna FLU NG de GSK B...
    Medical condition: Inmunización frente a la gripe estacional de varones y mujeres de 65 años y mayores o de 18 a 40 años Immunization against seasonal influenza in men and woman aged 65 years and older or 18 to 40 y...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Nov 04 01:45:57 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA